MinterEellison secures injunction win for Sandoz in Federal Court of Australia
Sep 15, 2025
•1 minute read
In this article:
Federal Court dismissed Regeneron and Bayer's interlocutory injunction application seeking to prevent Sandoz from launching biosimilar aflibercept products AFQLIR® and ENZEEVU® for treating eye conditions. Justice Helen Rofe delivered judgment on September 3, 2025, after six weeks of proceedings. MinterEllison represented Sandoz, led by partner Robert Cooper. The dispute involved Regeneron/Bayer's top-selling drug EYLEA® facing its first biosimilar competitor. Decision clears way for Sandoz's market entry in Australia.
Read the full story on Minterellison